A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.
The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.
The user experienced hair loss and started using minoxidil (5%) and finasteride (0.5 mg daily) with inconsistent application but still saw noticeable improvements by the end of January. They use the liquid form of minoxidil.
A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.
Topical finasteride concentrations and application amounts are debated, with concerns that mainstream solutions may use arbitrary concentrations. A 0.25% solution with a specific application method is suggested as more appropriate than higher concentrations.
OP underwent a hair transplant (HT) and has been using finasteride for one year. Despite having thin hair, OP is happy with the results and feels more confident.
A user underwent a 5000 graft hair transplant in Istanbul, which included 900 beard grafts, after previously using finasteride with limited success. The procedure cost £4500, including transport and aftercare in both Istanbul and the UK.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
A 19-year-old experienced significantly low testosterone levels after one month of taking finasteride. Suggestions included checking test units, retesting, and exploring other potential causes.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
A user shared their positive experience with finasteride and a 1000 FUE hair transplant for the frontal region, noting significant improvement in the crown area with medication alone. They emphasized patience with finasteride, as results vary from person to person.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
A 23-year-old is considering using a topical solution of Finjuve (finasteride and minoxidil) at a reduced dosage of 0.2/0.4mg to treat crown thinning while minimizing side effects. Applying 0.1-0.2 mL is suggested to lower systemic absorption and effectively reduce DHT on the scalp.
The user shared progress pictures of their hair growth after using finasteride, oral minoxidil, and undergoing a hair transplant with 4,200 grafts in Istanbul. They reported thicker hair and noticeable crown regrowth, with no side effects from the treatments.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
A 25-year-old man had a 3500 graft hair transplant on the frontal region and is happy with the results after 8 months. He has been on minoxidil and finasteride, switched to dutasteride, added ketoconazole shampoo for seborrheic dermatitis, and is considering a second transplant for the mid scalp/crown.
The conversation discusses concerns about brain fog potentially caused by finasteride use, with some users sharing personal experiences of cognitive issues and others suggesting it might be paranoia or unrelated. The original poster decides to stop using finasteride to see if their cognitive function improves.
The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.
A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.